Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00571519. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Participants who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments.
Study identification
- NCT ID
- NCT00571519
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- rivoglitazone HCl Drug
- placebo Drug
- pioglitazone HCl Drug
- pioglitazone HCl 45 mg Drug
- metformin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2007 (Actual)
- Primary completion
- May 23, 2008 (Actual)
- Completion
- May 23, 2008 (Actual)
- Last update posted
- May 26, 2021
2007 – 2008
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | Huntsville | Alabama | 35802 | — |
| Not listed | San Diego | California | 92128 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Ridgefield | Connecticut | 06877 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Pembroke Pines | Florida | 33026 | — |
| Not listed | Port Gibson | Mississippi | 39150 | — |
| Not listed | Las Vegas | Nevada | 89119 | — |
| Not listed | Albuquerque | New Mexico | 87109 | — |
| Not listed | Kettering | Ohio | 45429 | — |
| Not listed | Fleetwood | Pennsylvania | 19522 | — |
| Not listed | Harrisburg | Pennsylvania | 17112 | — |
| Not listed | Simpsonville | South Carolina | 29681 | — |
| Not listed | Daingerfield | Texas | 75638 | — |
| Not listed | Dallas | Texas | 75216 | — |
| Not listed | Plano | Texas | 75093 | — |
| Not listed | San Antonio | Texas | 78205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00571519, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00571519 live on ClinicalTrials.gov.